Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$614M |
| 2 |
Apple
AAPL
|
+$443M |
| 3 |
BLD
TopBuild
BLD
|
+$391M |
| 4 |
SPCX
SpaceX
SPCX
|
+$329M |
| 5 |
Penumbra
PEN
|
+$203M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.96B |
| 2 |
NVIDIA
NVDA
|
+$425M |
| 3 |
SNDK
Sandisk
SNDK
|
+$88M |
| 4 |
Southern Company
SO
|
+$80.6M |
| 5 |
PPL
PPL Corp
PPL
|
+$74.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.4% |
| 2 | Industrials | 13.64% |
| 3 | Consumer Discretionary | 9.5% |
| 4 | Healthcare | 7.9% |
| 5 | Financials | 5.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
United States Antimony
UAMY
$822M
| $192K | ﹤0.01% |
26,403
-3,444
| -12% | -$31.2K |
|
1427
ThredUp
TDUP
$366M
| $186K | ﹤0.01% |
27,130
-88,710
| -77% | -$415K |
|
|
STLN
1428
Starling Oncology
STLN
$658M
| $183K | ﹤0.01% |
33,644
+9,225
| +38% | +$38.8K |
|
1429
EverCommerce
EVCM
$1.7B
| $181K | ﹤0.01% |
+18,015
| New | +$191K |
|
1430
Arhaus
ARHS
$1.33B
| $175K | ﹤0.01% |
20,812
-27,773
| -57% | -$193K |
|
|
NAGE
1431
Niagen Bioscience
NAGE
$254M
| $174K | ﹤0.01% |
54,661
+32,539
| +147% | +$132K |
|
1432
PUT
Getty Images
GETY
$111M
| $172K | ﹤0.01% |
+200,000
| New | +$173K |
|
1433
Runway Growth Finance
RWAY
$278M
| $172K | ﹤0.01% |
+30,653
| New | +$194K |
|
1434
Janus International
JBI
$697M
| $167K | ﹤0.01% |
+30,054
| New | +$158K |
|
1435
Vanda Pharmaceuticals
VNDA
$319M
| $163K | ﹤0.01% |
26,637
-7,801
| -23% | -$51K |
|
1436
Cytek Biosciences
CTKB
$625M
| $160K | ﹤0.01% |
+36,140
| New | +$154K |
|
|
ARDT
1437
Ardent Health
ARDT
$1.55B
| $157K | ﹤0.01% |
15,960
-641,943
| -98% | -$6.09M |
|
1438
Janux Therapeutics
JANX
$1.06B
| $155K | ﹤0.01% |
10,079
-104,493
| -91% | -$1.51M |
|
|
SAAQW
1439
Space Asset Acquisition Corp Warrants
SAAQW
$5.41M
| $152K | ﹤0.01% |
168,334
-83,332
| -33% | -$68K |
|
1440
Xperi
XPER
$305M
| $150K | ﹤0.01% |
+18,283
| New | +$132K |
|
1441
Matrix Service
MTRX
$311M
| $150K | ﹤0.01% |
10,938
-52,779
| -83% | -$680K |
|
1442
Ginkgo Bioworks
DNA
$498M
| $148K | ﹤0.01% |
14,969
-50,794
| -77% | -$425K |
|
1443
BRC Group Holdings
RILY
$286M
| $148K | ﹤0.01% |
+18,445
| New | +$157K |
|
1444
Compass Therapeutics
CMPX
$432M
| $148K | ﹤0.01% |
67,478
+23,448
| +53% | +$69.2K |
|
1445
iShares Global Clean Energy ETF
ICLN
$2.09B
| $146K | ﹤0.01% |
7,134
-226
| -3% | -$4.69K |
|
1446
Envoy Medical
COCH
$57.9M
| $144K | ﹤0.01% |
+182,354
| New | +$124K |
|
1447
Q32 Bio
QTTB
$475M
| $144K | ﹤0.01% |
+11,336
| New | +$94.7K |
|
1448
NCR Voyix
VYX
$1.09B
| $142K | ﹤0.01% |
17,429
-364,630
| -95% | -$2.57M |
|
1449
Equillium
EQ
$146M
| $141K | ﹤0.01% |
+44,189
| New | +$106K |
|
1450
Payoneer
PAYO
$2.41B
| $130K | ﹤0.01% |
+18,247
| New | +$99.9K |
|
Similar funds
Michael Gelband's Q2 2026 Portfolio in Review
As of Q2 2026, Michael Gelband held 2,230 positions worth $15.5B, up 23% from $12.6B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Michael Gelband deployed $1.45B of net new capital in Q2 2026, opening 735 new positions and adding to 384 existing holdings. Its largest new stake was SpaceX: 1,938,935 shares worth $331M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Tesla, an estimated $1.96B trimmed.
- Michael Gelband's largest Q2 2026 buy was SpaceX: 1,938,935 shares worth $331M.
- Michael Gelband added most to Amazon in Q2 2026, an estimated $614M increase.
- Michael Gelband's biggest Q2 2026 reduction was Tesla, cutting an estimated $1.96B.
- Michael Gelband fully exited Southern Company in Q2 2026, selling an estimated $80.6M.
- Michael Gelband's ten largest holdings make up 31% of its $15.5B portfolio in Q2 2026.
- Michael Gelband opened 735 new positions and closed 720 in Q2 2026.
- Michael Gelband's portfolio value rose 23% quarter-over-quarter to $15.5B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.